Loss of a part of chromosome 8p22, containing the gene LPL and amplifications of the field 8q24 comprising the c-myc oncogene are the most frequent chromosomal aberrations in prostate cancer. We aimed to find the frequency of these chromosomal abnormalities and assess their relationship to the prognosis of prostate cancer patients in relation to Gleason score and expression of p27Kip1. We chose a subgroup of 17 monitored patients who had died during five years following diagnosis, and a group of 31 surviving patients whose Gleason score exceeded 5 (Group of Gleason score 2-3). Owing to lack of tumor cells in puncture biopsies, we made hybridizations in situ and objectively evaluated the result in 35 patients out of 48. Amplification in the field for oncogene c-myc was found in 19 cases (54.2%), in 15 of these (78.9%) polyploidy of the chromosome 8 was also confirmed. Deletion of a part of chromosome 8p22 was found in 21 cases (60%). Normal findings were shown in 8 cases (22.8%) and genetic abnormalities were revealed in 27 patients (77.2%). A Chi-squared test showed the dependence of Gleason score on amplification of the c-myc gene in nonmetastasing prostate cancer. In the case of a Gleason score of group 3, abnormalities in amplification of c-myc were statistically more significant than a Gleason score of group 2 using significance according to the Fisher Exact Probability test (p=0.039). We showed that the level of expression of protein p27 Kip1 was related to abnormality of amplification of the c-myc gene. We also came to the conclusion that decreased expression of protein p27 Kip1 is related the c-myc amplification.

• MeSH
• amplifikace genu MeSH
• chromozomální aberace * MeSH
• chromozomální delece MeSH
• hybridizace in situ fluorescenční MeSH
• imunoenzymatické techniky MeSH
• inhibitor p27 cyklin-dependentní kinasy metabolismus   MeSH
• lidé MeSH
• lidské chromozomy, pár 8 genetika   MeSH
• míra přežití MeSH
• nádory prostaty genetika   patologie   MeSH
• prognóza MeSH
• protoonkogenní proteiny c-myc genetika   metabolismus   MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Názvy látek
• inhibitor p27 cyklin-dependentní kinasy MeSH
• protoonkogenní proteiny c-myc MeSH

The loss of the 8p22 chromosome part and amplification of the 8q24 region (c-myc oncogene region) are the most frequent chromosomal aberrations observed in prostate carcinoma. We aimed to demonstrate the frequency of these chromosomal abnormalities and to assess how they correlate with the prognosis in patients with prostate carcinoma. From a set of 130 patients, we selected a group of 17 who died within five years after the diagnosis had been determined. Due to the lack of tumor cells in puncture biopsies, we managed to carry out in situ hybridization and assess the result objectively for 9 patients only. In seven cases, amplification of the region for c-myc oncogene was found; however, in five of them, polyploidy of chromosome 8 was manifested simultaneously. Deletion of the 8p22 chromosome part (region for the LPL gene) was found in five cases. A normal finding was detected in two cases. However, the analysis was carried out on a small number of cells gained from paraffin slices, so it was impossible to meet the requirement to examine 300 interphase cell nuclei. Therefore, we recommend to always determine whether the material taken is representative enough for this methodology and whether the tissue fixation is not inadequate or insufficient.

• MeSH
• amplifikace genu MeSH
• chromozomální aberace * MeSH
• chromozomální delece MeSH
• hybridizace in situ fluorescenční MeSH
• lidé středního věku MeSH
• lidé MeSH
• lidské chromozomy, pár 8 genetika   MeSH
• míra přežití MeSH
• nádory prostaty genetika   mortalita   MeSH
• polyploidie MeSH
• prognóza MeSH
• protoonkogenní proteiny c-myc MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Publikační typ
• anglický abstrakt MeSH
• časopisecké články MeSH
• Názvy látek
• protoonkogenní proteiny c-myc MeSH